Antisense therapeutics leader Ionis Pharmaceuticals (NASDAQ:IONS) and genomics and data insights company, Genuity Science, have entered a multi-year partnership. The collaboration is for the acceleration of the discovery and development of novel Therapeutics for around 20 diseases.
Ionis to leverage Genuity’s transformative whole-sequence genome
This partnership will be vital in allowing Ionis Pharmaceuticals to deliver transformative treatments to patients going forward. The approach of Genuity Sciences combines premium, whole sequence genome as well as deep phenotype information to offer better insight on an underlying disease mechanism. With the approach in combination with Ionis’ novel antisense tech, the companies will be able to accelerate the drug development process by direct targets translation into Therapeutics.
According to the terms of the agreement, Genuity Science will be eligible for development milestones and royalties from sales on top of an upfront payment. Brett Monia, the CEO of Ionis, said that the company’s financial strength and success validate antisense tech have positioned it to invest in the latest technologies that enhance their research and development capabilities. Monia added that the partnership with Genuity Sciences offers the company the potential to considerably enhance sits discovery opportunities and get more insight into the complexities of genetics.
Collaboration to accelerate delivery of new therapies
Rob Brainin, the CEO of Genuity Science, said that they are delighted to collaborate with Ionis, a leading innovation company. He added that the combination of scale and depth of the company’s assets and their analytical expertise and the antisense technology from Ionis can quickly translate information into insights that can deliver breakthrough therapies to more patients that need them.
Ionis’s antisense technology is a broadly applicable and efficient drug discovery platform that can treat various diseases that don’t have effective treatment alternatives. The drug discovery platform acts as a springboard for realized hope and actionable promise for patients with unmet medical needs. The company’s sights are set on the patients they are yet to reach with their over 40 medicines that can treat various diseases.
